Head and Neck Cancer, Thyroid Cancer
Conditions
Keywords
(DW)-MRI, oncological biomarkers, metastatic, recurrent, 18-063
Brief summary
Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. This makes specific organs, blood vessels, or tumors easier to see. Diffusion MRI lets us measure the motion of water in the tumor. The purpose of this study is to see if new MRI methods can give us more information about the tumor.
Interventions
OTHERMRI examinations
Patients will be imaged on a 1.5 T or 3 T MR scanner either from GE or Philips. Patients will receive a test-retest scan in on session prior to start of treatment. Patients who will be receiving radiation therapy treatment at main campus, will also be imaged weekly during their course of treatment.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 years * Group 1 patients: Presence of a suspicious metastatic lesion or suspicious for recurrent disease in the head and neck region. * Group 2 patients: * Biopsy proven recurrent or metastatic or definitive head and neck cancer or (differentiated and undifferentiated) thyroid cancers in the head and neck region only. * Patients planning to undergo reatment at MSK
Exclusion criteria
* Patient would require anesthesia for the study * Patients who are claustrophobic * Patients selecting treatment outside of MSK * Known reaction to Gd based contrast agent * Patients who have presence of a known contradiction to MRI * Pacemaker * Aneurysm clips * Patients with implants that are contradicted for MR imaging will be excluded * Pregnant * Age and mental status wherein he /she is unable to cooperate for MRI study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| For group 1: number of patients that have biomarkers that maybe early response to therapy indicators | 1 year | The study is designed to determine if the MRI will provide quantitative imaging biomarkers to predict or assess early treatment response in R/M head and neck cancers. The MR data will be compared with clinical follow-up data. Additional sequence parameters. |
| For group 2: number of patients response to treatment | 1 year | will be assessed using ROC curves with RECIST with the RECIST version 1.1 response as the gold standard and change in DW-MRI and image feature metrics as predictors. |
Countries
United States
Contacts
CONTACTAmita Dave, PhD
CONTACTAlan Ho, MD, PhD
PRINCIPAL_INVESTIGATORAmita Dave, PhD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed